Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
StockNews.AI · 2 hours
AI Summary
Labcorp announced expanded DPYD genotyping to detect all DPYD Tier 1/2 variants per AMP guidance, enabling safer, personalized cancer treatment. With 9% of patients carrying DPYD variants and about 1,300 US deaths from 5-FU toxicity annually, the move supports broader clinical adoption. The expansion strengthens Labcorp's pharmacogenomics and oncology offerings, potentially lifting test volumes over time.
Sentiment Rationale
The expansion to test all AMP-recommended DPYD variants may lift utilization of Labcorp's pharmacogenomics offerings, potentially increasing test volumes and revenue mix in oncology diagnostics over time. Positive regulatory framing (FDA warnings, CPIC/NCCN) supports adoption and payer coverage, contributing to a multi-quarter ramp rather than an immediate earnings beat.
Trading Thesis
Bullish over 6–12 months as DPYD testing expansion boosts Labcorp's oncology diagnostics growth.
Market-Moving
- Expanded DPYD testing could lift near-term Labcorp test volumes.
- Regulatory and clinical guidance backing DPYD testing may improve payer adoption.
- Long-standing DPYD testing footprint may accelerate revenue ramp versus peers.
- Potential geographic and clinic-network expansion supports demand.
Key Facts
- Labcorp expands DPYD genotyping to cover all AMP-recommended variants.
- Test identifies cancer patients at risk for severe chemotherapy toxicity.
- FDA labeling and CPIC/NCCN guidance back DPYD testing expansion.
- Labcorp has offered DPYD testing since 2006; 750M tests performed.
- Expansion strengthens Labcorp's pharmacogenomics and oncology portfolio.
Companies Mentioned
- Labcorp (LH): Expands DPYD genotyping; potential near-term revenue tailwind in pharmacogenomics.
- Association for Molecular Pathology (AMP): Guidance backing DPYD variant coverage; supports testing scope referenced in release.
Corporate Developments
Category: Corporate Developments. This is a strategic product expansion in Labcorp's pharmacogenomics and oncology services, signaling potential longer-term growth in the higher-value genomics testing segment.